Tag: RWE
EU-HTA 2026 Reality Check: What Pharma Must Get Right on JCA, RWE and Market Access
EU-HTA 2026 Reality Check: What Pharma Must Get Right on JCA, RWE and Market Access The European Union’s Health Technology Assessment framework is transforming how pharmaceutical companies prepare clinical evidence, demonstrate therapeutic value and plan market access across Europe. As Joint Clinical Assessment (JCA) implementation progresses, manufacturers face growing pressure to align clinical development, Real-World…
EU-HTA 2026: Can Pharma Fix PICO Challenges Before Phase III?
EU-HTA’s 2026 Scientific Consultation Window: Can Pharma Fix Tomorrow’s PICO Problems Before Phase III? Europe’s pharmaceutical evidence landscape is changing. Under the EU Health Technology Assessment (HTA) Regulation, generating strong clinical evidence is no longer sufficient on its own. Pharmaceutical companies must also consider whether their clinical development programmes will address the comparative evidence needs…
JCA to National Reimbursement: A Technical Evidence Framework
From JCA Relative Effects to National Reimbursement: Managing PICO Multiplicity, Indirect Comparisons and Residual Evidence Gaps The central technical challenge of the EU Health Technology Assessment Regulation is not simply producing a Joint Clinical Assessment (JCA) dossier on time. It is preserving the validity and decision relevance of one evidence package as it moves through…
EU JCA Evidence Requirements: Lessons for Pharma in 2026
EU JCA Is Now Operational: What the First Assessments Reveal About Evidence, RWE and Market Access The European Union’s Joint Clinical Assessment framework has moved decisively from policy into practice. Since the EU Health Technology Assessment Regulation became applicable in January 2025, pharmaceutical and biotechnology companies have been preparing for new timelines, evidence requirements and…
EMA and EU-HTA Alignment: One Evidence Strategy for Regulatory Approval and JCA
EMA and EU-HTA Alignment Building One Evidence Strategy for Regulatory Approval and Joint Clinical Assessment Europe’s evidence environment has entered a new phase. A medicine can now move through the European Medicines Agency’s regulatory assessment while, in parallel, entering the EU-level Joint Clinical Assessment process. These procedures remain legally and methodologically distinct, but manufacturers must…
EU HTA Is Changing European Market Access: Why Early Evidence Planning Is Now Essential
EU HTA Is Changing European Market Access: Why Early Evidence Planning Is Now Essential The European pharmaceutical industry is entering a new era. With the implementation of the European Union Health Technology Assessment (EU HTA) Regulation, companies must rethink how they generate clinical evidence, align cross-functional teams, and prepare for successful market access across Europe.…
Why Pharma Companies Should Stress-Test Their Market Access Strategy Before EU HTA Submission
Why Pharma Companies Should Stress-Test Their Market Access Strategy Before EU HTA Submission How pre-submission evidence reviews are becoming the next competitive advantage for pharmaceutical and biotech companies in Europe. The pharmaceutical industry has entered a new era of evidence generation. For years, achieving regulatory approval was considered the biggest milestone on the path to…
From Evidence Generation to Market Access: Why Integrated Evidence Planning Is Pharma’s Competitive Advantage Under EU HTA
From Evidence Generation to Market Access: Why Integrated Evidence Planning Is Becoming Pharma’s Competitive Advantage Under EU HTA How cross-functional collaboration, Real-World Evidence, AI, and early planning are reshaping successful market access strategies across Europe. The European pharmaceutical landscape is changing rapidly. Over the past year, discussions around the EU Health Technology Assessment (HTA) Regulation…
From Unstructured Data to Regulatory Decisions
From Unstructured Data to Regulatory Decisions: How AI Is Redefining Real-World Evidence The New Reality of Real-World Evidence (RWE) Real-World Evidence (RWE) has moved from the periphery of healthcare decision-making to the very center of regulatory, payer, and market access strategies. As regulators, HTA bodies, and healthcare systems increasingly rely on RWE to complement clinical…
AI & Machine Learning in Real-World Evidence
AI & Machine Learning in Real-World Evidence (RWE): Transforming Healthcare Insights Real-World Evidence (RWE) has become a powerful resource for healthcare innovation. It uses real-world data from sources like electronic health records, insurance claims, registries, and patient-reported outcomes to evaluate medical products and patient care. Artificial Intelligence (AI) and Machine Learning (ML) are reshaping how…
